The global Antimicrobial Peptides Service market size is predicted to grow from US$ 5.4 million in 2025 to US$ 6.6 million in 2031; it is expected to grow at a CAGR of 3.4% from 2025 to 2031.

Antimicrobial peptides (AMPs), also called host defense peptides (HDPs) are part of the innate immune response found among all classes of life. Fundamental differences exist between prokaryotic and eukaryotic cells that may represent targets for antimicrobial peptides. These peptides are potent, broad spectrum antibiotics which demonstrate potential as novel therapeutic agents. Antimicrobial peptides have been demonstrated to kill Gram negative and Gram positive bacteria, enveloped viruses, fungi and even transformed or cancerous cells. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as immunomodulators.

The major players in the industry are AnaSpec, AMP Biotech, Phoenix Biotech and Novabiotics, with revenues of about 7%, 9%, 3% and about 26% respectively in 2019.

By region, North America had the highest share of sales, at about 35%.

Infinity Market Research newest research report, the ?Antimicrobial Peptides Service Industry Forecast? looks at past sales and reviews total world Antimicrobial Peptides Service sales in 2024, providing a comprehensive analysis by region and market sector of projected Antimicrobial Peptides Service sales for 2025 through 2031. With Antimicrobial Peptides Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antimicrobial Peptides Service industry.

This Insight Report provides a comprehensive analysis of the global Antimicrobial Peptides Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antimicrobial Peptides Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Antimicrobial Peptides Service market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antimicrobial Peptides Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antimicrobial Peptides Service.

This report presents a comprehensive overview, market shares, and growth opportunities of Antimicrobial Peptides Service market by product type, application, key players and key regions and countries.

Segmentation by Type:

    AMPs Synthesis Service
    AMPs Activity Assay Service
    AMPs Development
    AMPs Modification and Design

Segmentation by Application:

    Enterprise
    Factory

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Profacgen
    LifeTein
    GenScript
    CPC Scientific
    Pepscan
    Creative Biolabs
    Creative Peptides
    Bachem
    Creative Proteomics